Article Information
vol. 31 no. 164
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 6, 2021
- Accepted February 7, 2022
- Published online April 13, 2022.
Copyright & Usage
Copyright ©The authors 2022 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Mohd Shariq1,6,
- Javaid A. Sheikh2,6,
- Neha Quadir1,3,
- Neha Sharma1,3,
- Seyed E. Hasnain4,5,7 and
- Nasreen Z. Ehtesham1⇑7
- 1ICMR-National Institute of Pathology, New Delhi, India
- 2Dept of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India
- 3Jamia Hamdard-Institute of Molecular Medicine, New Delhi, India
- 4Dept of Biochemical Engineering and Biotechnology, Indian Institute of Technology, New Delhi, India
- 5Dept of Life Science, School of Basic Sciences and Research, Sharda University, Greater Noida, India
- 6These authors contributed equally to this work
- 7These authors contributed equally to this article as lead authors and supervised the work
- Corresponding author: Nasreen Z. Ehtesham (nasreen.ehtesham{at}nip.gov.in)
Funding
Department of Biotechnology, Ministry of Science and Technology
BT/PR23099/NER/95/632/2017; BT/PR23155/NER/95/634/2017
Article usage
Altmetrics
Vol 31 Issue 164
Table of Contents
COVID-19 and tuberculosis: the double whammy of respiratory pathogens
Jump To
- Article
- Abstract
- Abstract
- Introduction
- SARS-CoV-2 and M. tb co-infection
- The clinical aspects of M. tb/SARS-CoV-2 co-infection
- The effect of bacillus Calmette–Guérin (BCG) vaccination on COVID-19
- SARS-CoV-2 treatment and possible interactions with TB co-infection/latent TB
- COVID-19 vaccines
- Diagnosis of M. tb/SARS-CoV-2
- Conclusions and perspectives
- Acknowledgements
- Footnotes
- References
- Figures & Data
- Info & Metrics